本文選題：前列康片 + 鹽酸坦索羅辛膠囊　； 參考：《中國(guó)老年學(xué)雜志》2017年21期

【摘要】：目的探討前列康片與鹽酸坦索羅辛聯(lián)合使用治療老年慢性前列腺炎患者的療效及其對(duì)患者前列腺液中炎性因子及免疫功能的影響。方法將老年慢性前列腺炎患者116例按隨機(jī)數(shù)字表法分為對(duì)照組和觀察組各58例。其中對(duì)照組口服鹽酸坦索羅辛膠囊,觀察組接受前列康片聯(lián)合鹽酸坦索羅辛膠囊治療,兩組均治療3個(gè)月,對(duì)比治療前后患者前列腺炎癥評(píng)分(NIH-CP SI)和總有效率,采用酶聯(lián)免疫吸附法(ELISA)測(cè)定治療前后患者前列腺液中白細(xì)胞介素(IL)-2、IL-6、IL-8、腫瘤壞死因子(TNF)-α水平,并對(duì)比兩組治療前后免疫細(xì)胞亞群的含量及不良反應(yīng)發(fā)生率。結(jié)果觀察組總有效率顯著高于對(duì)照組(P0.05)。治療3個(gè)月后觀察組NIH-CPSI總評(píng)分顯著低于對(duì)照組(P0.05)。治療前兩組免疫細(xì)胞亞群的含量無(wú)明顯差異(P0.05),治療3個(gè)月后兩組CD4~+/CD8~+比值均有回升,且觀察組顯著高于對(duì)照組(均P0.05)。治療3個(gè)月后兩組炎癥因子水平均顯著降低,且觀察組低于對(duì)照組(均P0.05)。兩組總不良反應(yīng)發(fā)生率比較無(wú)統(tǒng)計(jì)學(xué)差異(P0.05)。結(jié)論采用前列康片聯(lián)合鹽酸坦索羅辛膠囊治療老年慢性前列腺炎患者安全有效,并且可提高老年患者的免疫功能,降低前列腺液中炎癥因子的水平。
[Abstract]:Objective to investigate the effect of prostacon and tanzosoria hydrochloride in the treatment of senile chronic prostatitis and its effect on inflammatory factors and immune function in the prostatic fluid of the patients. Methods 116 elderly patients with chronic prostatitis were divided into control group and 58 cases in observation group according to random digital table method. Tansorosine capsule and the observation group were treated with proactive tablets combined with tanzosorine hydrochloride capsule. The two groups were treated for 3 months. The scores of prostatitis (NIH-CP SI) and total effective rate were compared before and after the treatment. The ELISA (enzyme linked immunosorbent assay) was used to determine the -2, IL-6, IL-8, and the cause of the tumor's bad death in the anterior gland fluid before and after treatment. The level of subgroup (TNF) - alpha and the incidence of adverse reactions in the immune cells before and after treatment in the two groups were compared. The total effective rate of the observation group was significantly higher than that of the control group (P0.05). The total NIH-CPSI score of the observation group was significantly lower than that of the control group (P0.05) after 3 months of treatment. There was no significant difference between the two groups of immune cell subgroups (P0.05) before treatment (P0.05), and 3 treatment groups. After month, the ratio of the two groups of CD4~+/CD8~+ increased, and the observation group was significantly higher than the control group (P0.05). After 3 months of treatment, the levels of inflammatory factors in the two groups were significantly lower, and the observation group was lower than the control group (P0.05). The incidence of total adverse reactions in the two groups was not statistically different (P0.05). Treatment of elderly patients with chronic prostatitis is safe and effective, and can improve the immune function of elderly patients, and reduce the level of inflammatory factors in prostatic fluid.

【作者單位】： 中南大學(xué)湘雅三醫(yī)院泌尿外科;長(zhǎng)沙市第三醫(yī)院泌尿外科;
【分類號(hào)】：R697.33

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 徐建軍,胡皓睿,吳洪波;鹽酸坦索羅辛治療良性前列腺增生癥50例報(bào)告[J];貴州醫(yī)藥;2001年01期

2 吳軍,孫波,拓西平,鄭家富;鹽酸坦索羅辛治療老年良性前列腺增生癥臨床療效觀察[J];解放軍保健醫(yī)學(xué)雜志;2001年03期

3 李勵(lì)獻(xiàn);陳寶玉;;鹽酸坦索羅辛治療早泄42例臨床觀察[J];海峽藥學(xué);2006年03期

4 成俊;宋師光;;鹽酸坦索羅辛治療慢性非細(xì)菌性前列腺炎合并早泄150例臨床觀察[J];新疆中醫(yī)藥;2010年04期

5 唐華;;鹽酸坦索羅辛治療良性前列腺增生癥132例臨床分析[J];中外醫(yī)療;2012年14期

6 鐘培聯(lián);楊誠(chéng);王睿;;鹽酸坦索羅辛膠囊聯(lián)合塞來(lái)昔布治療慢性非細(xì)菌性前列腺炎[J];中國(guó)醫(yī)藥科學(xué);2012年18期

7 魯功成;鹽酸坦索羅辛治療良性前列腺增生癥的初步體會(huì)[J];臨床泌尿外科雜志;1998年01期

8 常德貴 ,張蜀武 ,邵繼春;鹽酸坦索羅辛治療早泄65例臨床觀察[J];中國(guó)男科學(xué)雜志;2001年04期

9 王力,張江濤;鹽酸坦索羅辛治療早泄30例臨床觀察[J];長(zhǎng)治醫(yī)學(xué)院學(xué)報(bào);2003年02期

10 王力,張江濤,米磊;鹽酸坦索羅辛治療早泄30例臨床觀察[J];中國(guó)男科學(xué)雜志;2003年05期

相關(guān)會(huì)議論文 前10條

1 王鵬;謝建興;陳銘;關(guān)偉;郝燕;;益腎通和鹽酸坦索羅辛治療良性前列腺增生臨床療效觀察[A];中華醫(yī)學(xué)會(huì)第八次全國(guó)男科學(xué)學(xué)術(shù)會(huì)議論文集[C];2007年

2 孫中義;靳風(fēng)爍;李彥鋒;張克勤;梁培禾;;口服鹽酸氟西汀聯(lián)合口服鹽酸坦索羅辛治療早泄的臨床研究[A];第十五屆全國(guó)泌尿外科學(xué)術(shù)會(huì)議論文集[C];2008年

3 葉琪輝;夏宏輝;謝磊虞;曉勇;湯s，

本文編號(hào)：1779202